The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Role of transforming growth factor-α in von Hippel– Lindau (VHL) −/− clear cell renal carcinoma cell proliferation: A possible mechanism coupling VHL tumor suppressor inactivation and tumorigenesis
Open accessAbstract
Mutations of the VHL tumor suppressor gene occur in patients with VHL disease and in the majority of sporadic clear cell renal carcinomas (VHL −/− RCC). Loss of VHL protein function is associated with constitutive expression of mRNAs encoding hypoxia-inducible proteins, such as vascular endothelial growth factor. Overproduction of angiogenic factors might explain why VHL −/− RCC tumors are so highly vascularized, but whether this overproduction is sufficient for oncogenesis still remains unknown. In this report, we examined the activity of transforming growth factor-α (TGF-α), another VHL-regulated growth factor. We show that TGF-α mRNA and protein are hypoxia-inducible in VHL −/− RCC cells expressing reintroduced VHL. In addition to its overexpression by VHL −/− RCC cells, TGF-α can also act as a specific growth-stimulatory factor for VHL −/− RCC cells expressing reintroduced wild-type VHL, as well as primary renal proximal tubule epithelial cells, the likely site of origin of RCC. This role is in contrast to those of other growth factors overexpressed by VHL −/− RCC cells, such as vascular endothelial growth factor and TGF-β1, which do not stimulate RCC cell proliferation. A TGF-α-specific antisense oligodeoxynucleotide blocked TGF-α production in VHL −/− RCC cells, which led to the dependence of those cells on exogenous growth factors to sustain growth in culture. Growth of VHL −/− RCC cells was also significantly reduced by a drug that specifically inhibits the epidermal growth factor receptor, the receptor through which TGF-α stimulates proliferation. These results suggest that the generation of a TGF-α autocrine loop as a consequence of VHL inactivation in renal proximal tubule epithelial cells may provide the uncontrolled growth stimulus necessary for the initiation of tumorigenesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
Maxwell, P. H., Wiesener, M. S., Chang, G.-W., Clifford, S. C., Vaux, E. C., Cockman, M. E., Wykoff, C. C., Pugh, C. W., Maher, E. R., & Ratcliffe, P. J. (1999) · Nature · doi:10.1038/20459 · Cited by 5,180
Mutations of the VHL tumour suppressor gene in renal carcinoma
Gnarra, J. R., Tory, K., Weng, Y., Schmidt, L., Wei, M. H., Li, H., Latif, F., Liu, S., Chen, F., Duh, F.-M., et al. (1994) · Nature Genetics · doi:10.1038/ng0594-85 · Cited by 1,730
Self-citationOhh, M., Park, C. W., Ivan, M., Hoffman, M. A., Kim, T.-Y., Huang, L. E., Pavletich, N., Chau, V., & Kaelin, W. G. (2000) · Nature Cell Biology · doi:10.1038/35017054 · Cited by 1,577
A Specific Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase
Fry, D. W., Kraker, A. J., McMichael, A., Ambroso, L. A., Nelson, J. M., Leopold, W. R., Connors, R. W., & Bridges, A. J. (1994) · Science · doi:10.1126/science.8066447 · Cited by 806
Cited by
Rini, B. I., Campbell, S. C., & Escudier, B. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60229-4 · Cited by 1,621
Cohen, H. T., & McGovern, F. J. (2005) · New England Journal of Medicine · doi:10.1056/nejmra043172 · Cited by 1,554
Role of VHL Gene Mutation in Human Cancer
Kim, W. Y., & Kaelin, W. G. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.05.061 · Cited by 943
Raval, R. R., Lau, K. W., Tran, M. G. B., Sowter, H. M., Mandriota, S. J., Li, J.-L., Pugh, C. W., Maxwell, P. H., Harris, A. L., & Ratcliffe, P. J. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.13.5675-5686.2005 · Cited by 940
Molecular basis of the VHL hereditary cancer syndrome
Kaelin, W. G. (2002) · Nature Reviews Cancer · doi:10.1038/nrc885 · Cited by 865
Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein
Kondo, K., Klco, J., Nakamura, E., Lechpammer, M., & Kaelin, W. G. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00043-0 · Cited by 761
Inhibition of HIF2α Is Sufficient to Suppress pVHL-Defective Tumor Growth
Kondo, K., Kim, W. Y., Lechpammer, M., & Kaelin, W. G. (2003) · PLoS Biology · doi:10.1371/journal.pbio.0000083 · Cited by 611
Resistance to targeted therapy in renal-cell carcinoma
Rini, B. I., & Atkins, M. B. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70240-2 · Cited by 569
HIF activation identifies early lesions in VHL kidneys
Mandriota, S. J., Turner, K. J., Davies, D. R., Murray, P. G., Morgan, N. V., Sowter, H. M., Wykoff, C. C., Maher, E. R., Harris, A. L., Ratcliffe, P. J., et al. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00071-5 · Cited by 483
Smith, K., Gunaratnam, L., Morley, M., Franovic, A., Mekhail, K., & Lee, S. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0169 · Cited by 458
Self-citationRini, B. I., & Small, E. J. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.186 · Cited by 408
Rini, B. I., Campbell, S. C., & Rathmell, W. K. (2006) · Current Opinion in Oncology · doi:10.1097/01.cco.0000219260.60714.c4 · Cited by 379
Evaluation of HIF-1 inhibitors as anticancer agents
Semenza, G. L. (2007) · Drug Discovery Today · doi:10.1016/j.drudis.2007.08.006 · Cited by 363
The possible role of matrix metalloproteinase (MMP)-2 and MMP-9 in cancer, e.g. acute leukemia
Klein, G., Vellenga, E., Fraaije, M. W., Kamps, W. A., & de Bont, E. S. J. M. (2004) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2003.09.001 · Cited by 350
The von Hippel-Lindau Tumor Suppressor Protein and Clear Cell Renal Carcinoma
Kaelin, W. G. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1865 · Cited by 336
Kaelin, W. G. (2007) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev.pathol.2.010506.092049 · Cited by 336
Biology of hypoxia-inducible factor-2α in development and disease
Patel, S. A., & Simon, M. C. (2008) · Cell Death & Differentiation · doi:10.1038/cdd.2008.17 · Cited by 327
The Von Hippel-Lindau Tumor Suppressor Gene and Kidney Cancer
Kaelin, W. G. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-sup-040025 · Cited by 318
Maynard, M. A., Qi, H., Chung, J., Lee, E. H. L., Kondo, Y., Hara, S., Conaway, R. C., Conaway, J. W., & Ohh, M. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m208681200 · Cited by 283
Regulation of Angiogenesis by Hypoxia and Hypoxia‐Inducible Factors
Hickey, M. M., & Simon, M. C. (2006) · Current Topics in Developmental Biology · doi:10.1016/s0070-2153(06)76007-0 · Cited by 271
Franovic, A., Gunaratnam, L., Smith, K., Robert, I., Patten, D., & Lee, S. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0702387104 · Cited by 250
Self-citationThe von Hippel-Lindau gene, kidney cancer, and oxygen sensing.
Kaelin, W. G. (2003) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000092803.69761.41 · Cited by 135
Metadata
- Authors
- de Paulsen, N., Brychzy, A., Fournier, M.-C., Klausner, R. D., Gnarra, J. R., Pause, A., & Lee, S.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2001-02-06
- Volume
- 98
- Issue
- 4
- Pages
- 1387-1392
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2143793112
- Cited by
- 187
- References
- 4
- FWCI
- 10.48
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.